Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain : potential physiological benefits. / Ebdrup, Bjørn H; Knop, Filip K; Ishøy, Pelle L; Rostrup, Egill; Fagerlund, Birgitte; Lublin, Henrik; Glenthøj, Birte.
I: B M C Medicine, Bind 10, Nr. 1, 2012, s. 92.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain
T2 - potential physiological benefits
AU - Ebdrup, Bjørn H
AU - Knop, Filip K
AU - Ishøy, Pelle L
AU - Rostrup, Egill
AU - Fagerlund, Birgitte
AU - Lublin, Henrik
AU - Glenthøj, Birte
PY - 2012
Y1 - 2012
N2 - ABSTRACT: BACKGROUND: Antipsychotic-induced weight gain constitutes a major unresolved clinical problem which may ultimately be associated with reducing life expectancy by 25 years. Overweight is associated with brain deterioration, cognitive decline and poor quality of life, factors which are already compromised in normal weight patients with schizophrenia. Here we outline the current strategies against antipsychotic-induced weight gain, and we describe peripheral and cerebral effects of the gut hormone glucagon-like peptide-1 (GLP-1). Moreover, we account for similarities in brain changes between schizophrenia and overweight patients. DISCUSSION: Current interventions against antipsychotic-induced weight gain do not facilitate a substantial and lasting weight loss. GLP-1 analogues used in the treatment of type 2 diabetes are associated with significant and sustained weight loss in overweight patients. Potential effects of treating schizophrenia patients with antipsychotic-induced weight gain with GLP-1 analogues are discussed. CONCLUSIONS: We propose that adjunctive treatment with GLP-1 analogues may constitute a new avenue to treat and prevent metabolic and cerebral deficiencies in schizophrenia patients with antipsychotic-induced weight gain. Clinical research to support this idea is highly warranted.
AB - ABSTRACT: BACKGROUND: Antipsychotic-induced weight gain constitutes a major unresolved clinical problem which may ultimately be associated with reducing life expectancy by 25 years. Overweight is associated with brain deterioration, cognitive decline and poor quality of life, factors which are already compromised in normal weight patients with schizophrenia. Here we outline the current strategies against antipsychotic-induced weight gain, and we describe peripheral and cerebral effects of the gut hormone glucagon-like peptide-1 (GLP-1). Moreover, we account for similarities in brain changes between schizophrenia and overweight patients. DISCUSSION: Current interventions against antipsychotic-induced weight gain do not facilitate a substantial and lasting weight loss. GLP-1 analogues used in the treatment of type 2 diabetes are associated with significant and sustained weight loss in overweight patients. Potential effects of treating schizophrenia patients with antipsychotic-induced weight gain with GLP-1 analogues are discussed. CONCLUSIONS: We propose that adjunctive treatment with GLP-1 analogues may constitute a new avenue to treat and prevent metabolic and cerebral deficiencies in schizophrenia patients with antipsychotic-induced weight gain. Clinical research to support this idea is highly warranted.
U2 - 10.1186/1741-7015-10-92
DO - 10.1186/1741-7015-10-92
M3 - Journal article
C2 - 22891821
VL - 10
SP - 92
JO - BMC Medicine
JF - BMC Medicine
SN - 1741-7015
IS - 1
ER -
ID: 48454615